Isotechnnika Inc (ISA-T) Stock Predictions - Stockchase
WATCH LIST
13
Isotechnnika Inc (ISA-T)

ON STOCKCHASE SINCE May 2001

Merged with Aurinia (Sept 2013)

biotechnology/pharmaceutical

Isotechnnika Inc

ISA-T

3 watching          
Join the Discussion

Isotechnnika Inc (ISA-T) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about ISA-T



  • All
  • Filtered
Signal Opinion Expert
DON'T BUY
Isotechnnika Inc(ISA-T) 

November 18, 2008

Nothing fundamentally horrible about this company but it does have a small market cap, which is an out-of-favour sector. Small cap biotech sector is not a place to be.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Nothing fundamentally horrible about this company but it does have a small market cap, which is an out-of-favour sector. Small cap biotech sector is not a place to be.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Duncan Stewart

Director o, DSAM Consulting...

Price Price
$0.115
Owned Owned
No

DON'T BUY
Isotechnnika Inc(ISA-T) 

April 14, 2005

Drug development. Burning up cash hand over fist. In sloppy markets you have to watch out. There's no earnings or fundamental support. Very early stages in drug development and will have to raise money, so will dilute shareholders.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Drug development. Burning up cash hand over fist. In sloppy markets you have to watch out. There's no earnings or fundamental support. Very early stages in drug development and will have to raise money, so will dilute shareholders.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Chris Fernyc

Portfolio , Bissett Investment...

Price Price
$2.650
Owned Owned
No

WEAK BUY
Isotechnnika Inc(ISA-T) 

January 7, 2005

Their particular area of expertise is getting involved with drugs that are involved with transplants that reduce rejection. Outlook for the company is quite interesting. In phase 2 and 3 trials so they still have a ways to go. Speculative.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Their particular area of expertise is getting involved with drugs that are involved with transplants that reduce rejection. Outlook for the company is quite interesting. In phase 2 and 3 trials so they still have a ways to go. Speculative.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Floyd

President, R A Floyd Management...

Price Price
$2.180
Owned Owned
Yes

BUY
Isotechnnika Inc(ISA-T) 

January 26, 2004

Has a better product than cyclosporine. This should create a great marketplace for them. With more results coming out in 2004, you should see the stock move-up quite nicely.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Has a better product than cyclosporine. This should create a great marketplace for them. With more results coming out in 2004, you should see the stock move-up quite nicely.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Mike Weir

Managing D, Guardian Capital...

Price Price
$2.900
Owned Owned
Yes

BUY
Isotechnnika Inc(ISA-T) 

December 22, 2003

Thinks the stock should move up from this level. Have a good opportunity to bring their product to market. Should rally by the middle of 2004.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Thinks the stock should move up from this level. Have a good opportunity to bring their product to market. Should rally by the middle of 2004.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Mike Weir

Managing D, Guardian Capital...

Price Price
$2.670
Owned Owned
Yes

BUY
Isotechnnika Inc(ISA-T) 

September 9, 2003

Solid growth company. Well along in clinical trials. Well run and the upside is pretty good. Some good partnerships. Good product. If you want a Cdn biotech, this is a good one.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Solid growth company. Well along in clinical trials. Well run and the upside is pretty good. Some good partnerships. Good product. If you want a Cdn biotech, this is a good one.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$3.630
Owned Owned
Unknown

BUY
An interesting little company. Good cash position. Strong management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
An interesting little company. Good cash position. Strong management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Floyd

President, R A Floyd Management...

Price Price
$3.480
Owned Owned
Yes

BUY
Isotechnnika Inc(ISA-T) 

March 5, 2003

Has been able to meet ,ilestones.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Has been able to meet ,ilestones.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Mike Weir

Managing D, Guardian Capital...

Price Price
$3.100
Owned Owned
Unknown

BUY
Isotechnnika Inc(ISA-T) 

July 10, 2002

Strong joint venture. Should move up as the clinical trials go through.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Strong joint venture. Should move up as the clinical trials go through.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Floyd

President, R A Floyd Management...

Price Price
$4.050
Owned Owned
Unknown

BUY
Isotechnnika Inc(ISA-T) 

January 16, 2002

Prefers over Biomira.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Prefers over Biomira.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ray Steele

Vice Presi, Mavrix Fund Manageme...

Price Price
$4.050
Owned Owned
Unknown

TOP PICK
Isotechnnika Inc(ISA-T) 

November 13, 2001

Good product and is in phase 2. Volatile.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Good product and is in phase 2. Volatile.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Malvin Spooner

Chairman a, Mavrix Fund Manageme...

Price Price
$4.480
Owned Owned
Unknown

BUY
Isotechnnika Inc(ISA-T) 

November 9, 2001

Well funded in their product line.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Well funded in their product line.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Floyd

President, R A Floyd Management...

Price Price
$4.690
Owned Owned
Unknown

BUY
Expects it to get some partners.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Expects it to get some partners.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Malvin Spooner

Chairman a, Mavrix Fund Manageme...

Price Price
$3.700
Owned Owned
Unknown

Showing 1 to 13 of 13 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days